SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-22-068975
Filing Date
2022-11-03
Accepted
2022-11-03 16:06:22
Documents
40
Period of Report
2022-09-30

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT f10q0922_ayalapharma.htm   iXBRL 10-Q 519697
2 CERTIFICATION f10q0922ex31-1_ayala.htm EX-31.1 9755
3 CERTIFICATION f10q0922ex31-2_ayala.htm EX-31.2 9683
4 CERTIFICATION f10q0922ex32-1_ayala.htm EX-32.1 3914
5 CERTIFICATION f10q0922ex32-2_ayala.htm EX-32.2 3908
  Complete submission text file 0001213900-22-068975.txt   2407475

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE ayla-20220930.xsd EX-101.SCH 25137
7 XBRL CALCULATION FILE ayla-20220930_cal.xml EX-101.CAL 22958
8 XBRL DEFINITION FILE ayla-20220930_def.xml EX-101.DEF 114824
9 XBRL LABEL FILE ayla-20220930_lab.xml EX-101.LAB 231237
10 XBRL PRESENTATION FILE ayla-20220930_pre.xml EX-101.PRE 119011
34 EXTRACTED XBRL INSTANCE DOCUMENT f10q0922_ayalapharma_htm.xml XML 182069
Mailing Address 1313 N. MARKET STREET SUITE 5100 WILMINGTON DE 19801
Business Address 1313 N. MARKET STREET SUITE 5100 WILMINGTON DE 19801 (857) 444-0553
Ayala Pharmaceuticals, Inc. (Filer) CIK: 0001797336 (see all company filings)

IRS No.: 823578375 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39279 | Film No.: 221357933
SIC: 2836 Biological Products, (No Diagnostic Substances)